17.20
0.00
(0.00%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | - |
| 52 week | 10.85 - 18.10 |
| Open | - |
| Vol / Avg. | 200.00/852,137.00 |
| Mkt cap | 1.45B |
| P/E | - |
| Div/yield | - |
| EPS | -0.90 |
| Shares | 84.19M |
| Beta | 1.69 |
| Inst. own | 85% |
Events
Aug 2, 2013
Q4 2013 ImmunoGen, Inc. Earnings & FY2014 Guidance Conference Call
- 8:00AM EDT -
Aug 2, 2013
Q4 2013 ImmunoGen, Inc. Earnings Release & FY2014 Guidance release
- 6:30AM EDT -
Jun 13, 2013
ImmunoGen, Inc. at Goldman Sachs Healthcare Conference
- 12:20PM EDT -
Jun 5, 2013
ImmunoGen, Inc. at Jefferies Global Healthcare Conference
- 11:00AM EDT -
May 21, 2013
ImmunoGen, Inc. at Sachs Associates CANCER BIO PARTNERING FORUM Promoting Public & Private Sector,Collaboration & Investment in Drug Development
May 10, 2013
ImmunoGen, Inc. at Credit Suisse Antibody Day
Apr 12, 2013
ImmunoGen, Inc. Analyst & Investor Day
Mar 5, 2013
ImmunoGen, Inc. at Cowen Health Care Conference
Mar 5, 2013
ImmunoGen, Inc. at Credit Suisse Healthcare Conference
Feb 26, 2013
ImmunoGen, Inc. at RBC Capital Markets' Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -5.40% | -448.24% |
| Operating margin | -5.25% | -447.86% |
| EBITD margin | - | -419.54% |
| Return on average assets | -2.36% | -36.85% |
| Return on average equity | -3.94% | -65.50% |
| Employees | 245 | - |
| Carbon Disclosure Rating | - | - |
Address
830 Winter Street
WALTHAM, MA 02451-1477
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)
WALTHAM, MA 02451-1477
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after delivery to a cancer cell. An anticancer compound made using the Company�s Targeted Antibody Payload (TAP), technology consists of a monoclonal antibody. The Company's TAP technology is designed to enable the creation of well-tolerated anticancer products. As of June 30, 2012, ImmunoGen had three wholly owned clinical-stage product candidates included IMGN901, IMGN853, and IMGN529, and other TAP compounds in earlier stages of development.
Officers and directors
| Stephen C. McCluski | Independent Chairman of the Board | |
| Daniel M. Junius | President, Chief Executive Officer, Director | |
| Gregory D. Perry | Chief Financial Officer, Executive Vice President | |
| John M. Lambert Ph.D. | Executive Vice President - Research and Development, Chief Scientific Officer | |
| Charles Q. Morris | Executive Vice President, Chief Development Officer | |
| Craig Barrows | Vice President, General Counsel, Secretary | |
| James J. O'Leary M.D. | Vice President, Chief Medical Officer | |
| Theresa G. Wingrove Ph.D. | Vice President - Regulatory Affairs | |
| Peter J. Williams | Vice President - Business Development | |
| Mark Goldberg M.D. | Independent Director |